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Abstract Breast cancer is one of the most common
cancer and remains the leading cause of cancer-related
deaths in women. There is increasing evidence suggesting
that TRPM7 plays a pivotal role in breast cancer progres-
sion and metastasis. In this study, a case–control study was
carried out to investigate the effects of SNPs in TRPM7
genes in the development of breast cancer in Han Popu-
lation of Northeast China. A total of six SNPs (rs8042919,
rs4775899, rs11635825, rs7173321, rs616256, and
rs11070795) were chosen and genotyped. Genotypes were
analyzed using a single-base primer extension assay. Chi-
square (v2) test was used to analyze statistical difference
between control and patient groups in genotype and allele
frequencies. The genotype-specific risks and allele fre-
quencies of haplotypes in breast cancer patients and con-
trols were estimated by OR and 95 % confidence intervals.
The G allele of rs8042919 was associated with a reduced
disease risk. The G allele of rs7173321 and particularly its
homozygous GG genotype are associated with an increased
breast cancer risk. Two of the TRPM7 SNPs (rs8042919
and rs7173321) are associated with breast cancer patients
in Han Population of Northeast China.
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Introduction
Calcium and magnesium ions play a central role in many
cellular processes, including muscle contraction, transmit-
ter release, cell proliferation, differentiation, gene tran-
scription, apoptosis, and angiogenesis [1, 2]. Disordered
regulation of calcium and magnesium levels may also lead
to irregularities in many biological activities, even leading
to carcinogenesis. Transient receptor potential melastatin 7
channels are non-selective cation channels with predomi-
nant permeability for Ca2? and Mg2?. Activation of
TRPM7 is implicated in diverse physiological and patho-
logical processes, such as Mg2? homeostasis [3–6], cell
viability, growth and proliferation [7–9], anoxic neuronal
cell death [10], synaptic transmission, and cell adhesion
[11, 12]. It has been reported that TRPM7 is abundantly
expressed in a variety of human carcinoma cells, including
gastric adenocarcinoma cells [13], lung cancer cells [14],
and breast cancer cells [15].
We therefore hypothesized that TRPM7 gene variation
may contribute to the pathogenesis of human breast cancer.
The aim of this study was to evaluate the potential asso-
ciation of 8 TRPM7-tagging single-nucleotide polymor-
phisms (SNPs) with the risk of incident in breast cancer.
Materials and methods
Study subjects
A total of 945 women were in the present study, consisting
of 462 breast cancer cases and 483 controls that were
frequency-matched on age (within 5 years) and race. All
the individuals in this study were genetically independent
ethnic Han Chinese from Northeast China. All the eligible
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cases were ascertained through histopathology and treated
at the Department of Breast Surgery, Second Affiliated
Hospital of Harbin Medical University between 2006 and
2010, and the control subjects were selected from the
physical examination center during the same period.
Inclusion criterion for the control subjects was absent of
any clinical relevant malignancy at the beginning of the
study. Criteria for exclusion included benign breast dis-
ease, family history of breast cancer, and the use of hor-
mone replacement therapy. This project has been approved
by the Scientific and Ethical Committee of the Second
Affiliated Hospital of Harbin Medical University, and the
written informed consent was obtained from all study
participants. Baseline characteristics of study participants
are shown in Table 1.
Extraction of DNA
Peripheral blood samples (5 mL) were collected from all
the subjects in EDTA vacutainers and stored at -20 C
until further use. Genomic DNA was extracted using
Omega blood DNA extraction kit (US) as per the instruc-
tions of the manufacturer. DNA concentrations were
monitored using a Nanodrop spectrophotometer (US) and
then stored at -20 C until genotyping.
SNP selection and genotype determination
We surveyed common SNPs from the public accessible
database, the National Center for Biotechnology Information
database SNP (NCBI dbSNP) supplemented by the CHB
HapMap database of the International HapMap project. We
selected a set of tagging SNPs that capture common variation
and linkage disequilibrium (LD) structure across the TRPM7
gene using the Tagger program implemented in Haploview
4.2 software. Selection of tagging SNPs was based on a
pairwise correlation coefficient (r-square) of 0.80 or
greater—between tagging SNPs and untyped SNPs and a
minor allele frequency (MAF) of 5 % or greater. A total of 6
SNPs identified [dbSNP rs8042919, rs4775899, rs11635825,
rs7173321, rs616256, and rs11070795] were chosen and
genotyped.
Genotypes were analyzed using a single-base primer
extension assay with the SNaPshot Multiplex Kit, accord-
ing to the manufacturer’s protocol (Applied Biosystems,
Foster City, CA, USA). The sequences of PCR products
were analyzed by electrophoresis on an ABI Prism 3730
DNA Analyzer. The primer sequences are shown in
Table 2. Five percent of the selected randomly samples
were re-genotyped for quality control (100 % concordance
rate). Results were scored blinded as to case–control status.
Statistical analysis
The difference in variable means (e.g., age) between con-
trol and patient groups was analyzed by Student’s t test.
Chi-square (v2) test was used to analyze statistical differ-
ences between control and patient groups in genotype and
allele frequencies. The genotype-specific risks and allele
frequencies of haplotypes in breast cancer patients and
controls were estimated as odds ratio (OR) and 95 %
confidence intervals (CI). A P value of \0.05 was con-
sidered statistically significant. Statistical analysis was





Age (years) 49.1 ± 7.2 47.3 ± 6.9
Cigarette smoking (n) 25 (5.4 %) 24 (5.0 %)
Alcohol drinking (n) 65 (14.1 %) 71 (14.7 %)
Age at first menstruation (years) 13.1 ± 1.2 13.4 ± 1.2
Breastfeeding (n) 284 (61.5 %) 311 (64.4 %)
Menopause (n) 145 (31.3 %) 139 (28.8 %)
Table 2 Description of the
investigated TRPM7 SNPs
Position SNP ID Functional MAF Alleles Primer sequences
48665962 rs8042919 Exon28 0.078 G/A F: 50-GCACCATTCACTGCTCATGT-30
R: 50-CCATTGGTGTCCAGGTAGAA-30
48709892 rs7173321 Intron 0.078 C/G F: 50-CTTGATACCATGATTCCAGATGA-30
R: 50-TTTTAGGACTAAGGGATTGAAGC-30
48640664 rs11070795 UTR-3 0.356 A/G F: 50-TTGCTGACTCCAGCACAGTT-30
R: 50-ATATGGAGCCTAACCCTGATTC-30
48640863 rs616256 UTR-3 0.411 G/A F: 50-TTGCTGACTCCAGCACAGTT-30
R: 50-ATATGGAGCCTAACCCTGATTC-30
48755015 rs4775899 Intron 0.409 C/T F: 50-GAGGCAGGAGAATCGACTGA-30
R: 50-GGCACATTTGATTGGGTAACT-30
48742239 rs11635825 Intron 0.078 T/C F: 50-ACCCAGTAGATGCCCAATAGA-30
R: 50-TCCAAGGACCCTCACAGGTA-30
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performed by SAS 9.1 for Windows (SAS Institute Inc.,
Cary, NC, USA).
Results
The allele and genotype distribution of the TRPM7 SNPs
are shown in Tables 3 and 4. No significant deviation from
Hardy–Weinberg equilibrium was observed for any SNP.
An association was observed between breast carcinoma
occurrence and the presence of two SNPs, namely
rs8042919 (A/G) located in exon 28 and rs7173321 (G/C)
located in intron 10–11. The rs8042919 genotypic distri-
butions were determined as 81.1 % for the GG, 18.2 % for
the heterozygous GA status, and 0.7 % for the AA,
respectively, in breast cancer parameters. The homozygous
GG genotype was seen in lower percentage of patients with
breast cancer (81.1 %) when compared to healthy women
(88.2 %), and the OR for the GG versus GA?AA was [OR
0.577 (0.402–0.828); P = 0.003]. Frequency of G/A allele
was 834/90 and 905/61 among patients and controls,
respectively [OR 0.625 (0.445–0.876); P = 0.006]. The
rs7173321 genotypic distributions were determined as
65.1 % for the CC, 28.8 % for the heterozygous CG status,
and 6.1 % for the GG, respectively, in breast cancer
parameters, and displayed 69.8 % for the CC, 27.1 % for
the heterozygous CG status, and 3.1 % for the GG,
respectively, in controls. The homozygous GG genotype
was seen in high percentage of patients with case when
compared to controls. Results showed that GG versus
CC?CG genotypes exhibited a significant difference
between patients and controls [OR 2.013 (1.061–3.820);
P = 0.029]. Frequency of G allele was 0.205 and 0.167
between breast cancer parameters and controls, respec-
tively [OR 0.078 (0.616–0.982); P = 0.034].
Discussion
Breast cancer is a complex disease, which is influenced by
a variety of genetic, environmental, and lifestyle factors.
Genetic factor is an important contributor to breast cancer
susceptibility. Recently, in unselected breast cancer
patients, several genome-wide association studies (GWAS)
or studies of specific candidate single-nucleotide poly-
morphisms (SNPs) have a number of novel genetic sus-
ceptibility variants and loci, including fibroblast growth
factor receptor 2 (FGFR2), trinucleotide-repeat-containing
Table 3 Genotyping and allele
frequency of TRPM7 gene in










GG 375 (81.1) 426 (88.2) G 834 (90.3) 905 (93.7)
GA 84 (18.2) 53 (11.0) A 90 (9.7) 61 (6.3)
AA 3 (0.7) 4 (0.8)
rs7173321
CC 301 (65.1) 337 (69.8) C 735 (79.5) 805 (83.3)
CG 133 (28.8) 131 (27.1) G 189 (20.5) 161 (16.7)
GG 28 (6.1) 15 (3.1)
rs11070795
AA 213 (46.1) 236 (48.9) A 626 (67.7) 667 (69.0)
AG 200 (43.3) 195 (40.4) G 298 (32.3) 299 (31.0)
GG 49 (10.6) 52 (10.7)
rs616256
GG 166 (35.9) 198 (41.0) G 538 (58.2) 603 (62.4)
GA 206 (44.6) 207 (42.9) A 386 (41.8) 363 (37.6)
AA 90 (19.5) 78 (16.1)
rs4775899
CC 141 (30.5) 148 (30.6) C 522 (56.5) 555 (57.5)
CT 240 (52.0) 259 (53.6) T 402 (43.5) 411 (42.5)
TT 81 (17.5) 76 (15.7)
rs11635825
TT 324 (70.1) 341 (70.6) T 767 (83.0) 804 (83.2)
TC 119 (25.8) 122 (25.3) C 157 (17.0) 162 (16.8)
CC 19 (4.1) 20 (4.1)
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9 (TNRC9), mitogen-activated protein kinase kinase kinase
1 (MAP3K1), leukocyte-specific protein 1 (LSP1), mito-
chondrial ribosomal protein S30 (MRPS30), SLC4A7,
transforming growth factor beta 1 (TGFB1), COX11,
TOX3/LOC643714, estrogen receptor alpha (ESR1), Cas-
pase-8 (CASP8), or chromosome 8q24 and 2q3, which
were independently associated with an increased risk of
breast cancer [16–19], and research in this area is still in
continuous progress.
TRPM7 is a divalent cation-selective ion channel that is
permeable to Ca2? and Mg2?. Studies indicate that alter-
ations in both calcium homeostasis and ion channel
expression could play a key role in the regulation of pro-
cesses, such as proliferation, differentiation, apoptosis, and
oncogenesis. Recently, its expression was found in cancer
cells, such as retinoblastoma, head and neck cells, gastric,
and pancreatic cancer cells [13, 20, 21]. Guilber et al. [15]
found that functional TRPM7 channel is expressed in
human breast cancer cells and is related to the breast cancer
cell proliferation. The study shows that TRPM7 is over-
expressed in breast tumor tissues when compared to the
adjacent non-tumor ones. TRPM7 is frequently expressed
in the poorly differentiated and highly proliferative breast
cancers (grade III, high Ki67), so it may be considered as a
proliferative marker of poorly differentiated tumors [22].
TRPM7 was also found to be involved in breast cancer cell
metastasis [13]. Thus, these previous reports suggest a
functional involvement of the TRPM7 gene in the patho-
physiology of breast cancer. To date, no study has assessed
genetic variation in TRPM7 gene or its contribution to
susceptibility to breast cancers. SNPs are the most common
sources of human genetic variation, and they may con-
tribute to an individual’s susceptibility to cancer.
In this case–control study, we found that the rs8042919
(A/G) and rs7173321 (G/C) polymorphisms of TRPM7
gene were associated with breast cancer risk in Han Pop-
ulation of Northeast China. Our results indicated the
rs8042919 homozygous GG genotype was seen in lower
percentage of patients with breast cancer (81.1 %) when
compared to healthy women (88.2 %), and the odds ratios
(OR) for the GG versus GA?AA were [OR 0.577
(0.402–0.828); P = 0.003]. Frequency of G allele was
0.903 and 0.937 among patients and controls, respectively
[OR 0.625 (0.445–0.876); P = 0.006]. Therefore, we think
the G allele of rs8042919 has the significant protective
effect, which was associated with a reduced disease risk. A
Table 4 TRPM7 gene
polymorphisms and breast
cancer risk
OR odds ratio, CI confidence
interval






OR 95 %CI P value
rs8042919
GG/GA?AA 375/87 426/57 0.577 (0.402–0.828) 0.003*
AA/GG?GA 3/459 4/479 0.783 (0.174–3.516) 0.749
G/A 834/90 905/61 0.625 (0.445–0.876) 0.006*
rs7173321
CC/GG?CG 301/161 337/146 0.810 (0.617–1.064) 0.129
GG/CC?CG 28/434 15/468 2.013 (1.061–3.820) 0.029*
C/G 735/189 805/161 0.778 (0.616–0.982) 0.034*
rs11070795
AA/GG?AG 213/249 236/247 0.895 (0.693–1.156) 0.396
GG/AA?AG 49/413 52/431 0.983 (0.651–1.486) 0.937
A/G 626/298 667/299 0.942 (0.776-1.143) 0.544
rs616256
GG/AA?GA 166/296 198/285 0.807 (0.621–1.050) 0.110
AA/GG?GA 90/372 78/405 1.256 (0.899–1.755) 0.181
G/A 538/386 603/363 0.839 (0.698–1.009) 0.062
rs4775899
CC/TT?CT 141/321 148/335 0.994 (0.754–1.311) 0.967
TT/CC?CT 81/381 76/407 1.139 (0.808–1.604) 0.458
C/T 522/402 555/411 0.962 (0.801–1.154) 0.674
rs11635825
TT/CC?TC 324/138 341/142 0.978 (0.739–1.293) 0.874
CC/TT?TC 19/443 20/463 0.993 (0.523–1.885) 0.983
T/C 767/157 804/162 0.984 (0.774–1.252) 0.898
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check of the SNP database reveals that the T1482I variant
of the TRPM7 gene was identified in other populations
(Reference SNP ID no. rs8042919) studied by Perlegen
(http://www.ncbi.nih.gov/SNP) and the International Hap-
Map Project (http://www.hapmap.org). We speculate that
T1482I variant could be one of many contributory factors
to cause breast cancer. In murine TRPM7, Ser-1482 is
potential substrates for autophosphorylation by the C-ter-
minus serine/threonine a-kinase domain. However, the Ile-
1482 mutation found in these patients cannot be phos-
phorylated. On the other hand, when recombinant TRPM7
with the T1482I mutation was heterologously expressed in
HEK-293 cells, channels remained functional but showed
increased sensitivity to Mg2? inhibition and reduced
phosphorylation as compared with the wild type. A variant
of TRPM7 with a missense mutation (T1482I) is found in a
subset of patients with Guamanian amyotrophic lateral
sclerosis (ALS-G) and parkinsonism dementia (PD-G) [23,
24]. Also, some researchers believe it is unlikely that
T1482I or TRPM7 is associated with the Kii-ALS/PDC
[25]. It needs to be proved whether variant of T1482I can
be induced by rs8042919 polymorphism in breast cancer
patients, and variant of T1482I leads to changes in the
structure and function of TRPM7 gene. Also, it is our
direction to work further. We hope that we can reduce the
risk of breast cancer by analyzing the genetic variation of
rs8042919.
Our study demonstrated that homozygous genotype GG
of rs7173321 was more frequent in breast cancer patients.
The G allele of polymorphism rs7173321 and particularly
its homozygous GG genotype are associated with an
increased breast cancer risk and thus could be risk factors
for breast cancer development. Previous studies found that
no significant evidence which the rs7173321 and
rs8042919 polymorphisms are related to diabetes and
incident ischemic stroke could be discovered [26–28]. And
they hypothesize that TRPM7, as a housekeeping gene-
regulating cellular magnesium metabolism, may truly have
limited genetic variability [28]. However, it is surprising
for us to find that there is weak association between
TRPM7 genetic variants and breast cancer. We speculate
that the inconsistency maybe results from small sample
sizes, false positives, genetic heterogeneity among differ-
ent populations, and disease.
In conclusion, the data indicated that TRPM7 genes
polymorphism was likely associated with breast cancer in
Han Population of Northeast China. The G allele of
rs8042919 was associated with a reduced disease risk,
while the G allele of rs7173321 and particularly its
homozygous GG genotype were associated with an
increased breast cancer risk. Thus, TRPM7 polymorphism
might be one of candidates for the genetic marker to screen
the risk of breast cancer.
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